You are here
P&T June 2017
This article, the first in a series of three, introduces cancer immunology, cancer immunotherapy strategies, and the classes of anticancer therapeutic agents.
Newer atypical antipsychotics have favorable safety and efficacy profiles, but their use is often limited by high cost. The authors present one institution’s antipsychotic tablet-splitting program that resulted in substantial savings.
The rising cost of cancer treatments has prompted institutions to employ cost-saving, reimbursement-maximizing strategies. After implementing a policy governing inpatient administration of antineoplastic medications, one community teaching hospital successfully decreased the associated drug costs.
We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.
The latest in hepatology research was presented at this year’s European Association for the Study of the Liver (EASL) International Liver Congress.
Highlights of the AMCP Annual Meeting included marketplace trends, the affordability crisis, and the issues facing value-based contracting.
Unverified patient-reported errors can have real consequences
Drug companies breathe easier as PDUFA VI heads for approval
Approvals, new indications, regulatory activities, and more
Ribociclib (Kisqali) for HR+/HER2− advanced or metastatic breast cancer in postmenopausal women; safinamide (Xadago) as adjunctive treatment for patients with Parkinson’s disease; and avelumab (Bavencio) for metastatic Merkel cell carcinoma
Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson’s disease